The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves' Ophthalmopathy Patients | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!
Scientific Articles

The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves’ Ophthalmopathy Patients

key information

source: Pharmacology

year: 2017

authors: Li J, Xiao Z, Hu X, Li Y, Zhang X, Zhang S, Gong W, Zhao J, Ye X

summary/abstract:

Purpose:
The purpose of this study is to examine the effectiveness of introducing both rituximab (RTX) and 131I for active Graves’ ophthalmopathy (GO) with hyperthyroidism.

Methods:
In total, 217 patients suffering from active GO with hyperthyroidism were included in this research. All subjects were randomly assigned to 3 groups. Patients in group A solely received 131I treatment; group B1 underwent a methylprednisolone treatment in combination with 131I treatment; and group B2 received an RTX in combination with 131I treatment. Hyperthyroidism treatment outcomes, orbital volumetry, ophthalmic assessments, serum cytokine levels, and adverse effects were measured after treatment.

Results:
The orbital volumetry principle was significantly different from 24 weeks after the start of treatment among all 3 groups, and improvements in most ophthalmic parameters were regarded significantly different among 3 groups (all p < 0.05). The expression levels of miR-146a and most serum cytokines were regarded significantly different from 24 weeks after the start of treatment among 3 groups (all p < 0.05).

Conclusions:
In comparison with other therapies, RTX treatment in combination with 131I treatment is considered to be more effective for hyperthyroidism with active GO.

organization: Yinzhou Hospital of Ningbo University Medical College, China

DOI: 10.1159/000453618